Skip to main content
Premium Trial:

Request an Annual Quote

RNA and Sequencing Chemistry Shop Quiatech Changes Name to Oligovation

NEW YORK (GenomeWeb News) — Quiatech, a developer of genetics-enabling technologies, has changed its name to Oligovation, the company said yesterday.
 
Oligovation said it has a modified RNA chemistry that improves synthesis conditions for RNA production, a specific reversible terminator for improving sequencing technology, and an in situ amplification technology for in vitro diagnostics.
 
The firm, based in Uppsala, Sweden, said it made the change as it prepares to market “a range of DNA and RNA technologies” it developed under the name Quiatech.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.